# HealthEquity, Inc. (HQY) Stock Analysis: Analysts See Potential 61% Upside

- Link: https://www.directorstalkinterviews.com/healthequity-inc-hqy-stock-analysis-analysts-see-potential-61-upside/4121240052
- Published: 2026-02-16T11:31:02+00:00
- Author: Madison Wilson

HealthEquity, Inc. (NASDAQ: HQY), a prominent player in the Health Information Services
industry, is capturing investor attention with its robust growth potential and attractive
analyst ratings. As a technology-enabled service provider, HealthEquity offers a
comprehensive platform that supports thousands of Americans in managing their health
savings accounts (HSAs) and other benefit programs. With a market capitalization
of $6.39 billion, the company is a significant entity within the healthcare sector.

Currently trading at $73.88, HealthEquity’s stock price is situated near the lower
end of its 52-week range of $73.21 to $113.78. Despite the modest price change of
0.67 (0.01%) on the day, the stock presents an intriguing entry point for investors
considering its potential upside. Analysts have set a target price range between
$86.00 and $130.00, with an average target of $119.13, suggesting a substantial 
upside potential of 61.24% from current levels.

The company’s valuation metrics indicate a forward P/E ratio of 16.18, which is 
appealing for investors focusing on growth at a reasonable price. HealthEquity’s
revenue growth stands at an impressive 7.20%, reflecting its ability to expand its
services and capture a larger market share. The company has reported an EPS of 2.18
and a return on equity of 9.01%, demonstrating efficient management and a solid 
return on investments.

HealthEquity’s financial health is further underscored by its free cash flow of 
$279,539,744, providing a strong foundation for future expansions and potential 
acquisitions. However, it is notable that the company does not currently offer a
dividend, with a payout ratio of 0.00%. This aligns with its strategy of reinvesting
earnings to drive growth rather than returning capital to shareholders through dividends.

A key factor that sets HealthEquity apart is the overwhelmingly positive sentiment
from analysts. With 14 buy ratings, 1 hold rating, and only 1 sell rating, the consensus
suggests a strong belief in the company’s growth prospects. This sentiment is particularly
compelling given the technical indicators, where the stock is trading below both
its 50-day and 200-day moving averages of 88.78 and 94.54, respectively. The RSI(
14) is at 19.92, indicating the stock is currently in oversold territory, which 
could signal a potential buying opportunity.

HealthEquity’s innovative approach, offering a blend of health savings accounts 
and other financial services to consumers and employers, positions it well in a 
market that increasingly values integrated, technology-driven solutions. Its partnerships
with health plans, benefits administrators, and brokers enhance its distribution
capabilities, allowing it to reach a wide audience effectively.

While the MACD of -3.94 and signal line of -3.30 suggest bearish momentum in the
short term, the underlying fundamentals and analyst optimism present a compelling
case for long-term investors. As HealthEquity continues to leverage its technology
platform and expand its service offerings, it remains a noteworthy option for investors
seeking exposure to the confluence of healthcare and financial services.

Share on: